Fidia entered the regenerative medicine segment with U.S. launch of NuDYN™ acellular amnion-derived injectable allograft. The shelf-stable, flowable allograft is the first product in the company’s new orthobiologic portfolio, and complements Fidia’s current hyaluronic acid-based HYALGAN® and HYMOVIS® products, which are used to treat osteoarthritis knee pain.
In the U.S., Fidia seeks to diversity into new, emerging product categories to serve patients who seek non-surgical solutions.
NuDYN does not require any reconstitution. As a true acellular amnion-derived allograft without any chorion, the product is non-immunogenic. Third-party CLIA-certified labs conduct serological and endotoxin testing that exceed FDA requirements to ensure the safety and quality of this product.
Fidia entered the regenerative medicine segment with U.S. launch of NuDYN™ acellular amnion-derived injectable allograft. The shelf-stable, flowable allograft is the first product in the company's new orthobiologic portfolio, and complements Fidia's current hyaluronic acid-based HYALGAN® and HYMOVIS® products, which are used to treat...
Fidia entered the regenerative medicine segment with U.S. launch of NuDYN™ acellular amnion-derived injectable allograft. The shelf-stable, flowable allograft is the first product in the company’s new orthobiologic portfolio, and complements Fidia’s current hyaluronic acid-based HYALGAN® and HYMOVIS® products, which are used to treat osteoarthritis knee pain.
In the U.S., Fidia seeks to diversity into new, emerging product categories to serve patients who seek non-surgical solutions.
NuDYN does not require any reconstitution. As a true acellular amnion-derived allograft without any chorion, the product is non-immunogenic. Third-party CLIA-certified labs conduct serological and endotoxin testing that exceed FDA requirements to ensure the safety and quality of this product.
Copy to clipboard 
